GlaxoSmithKline Reaches New 52-Week High (GSK)
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
NEW YORK (TheStreet) -- GlaxoSmithKline (GSK">GSK) hit a new 52-week high Wednesday as it is currently trading at $50.18, above its previous 52-week high of $50.16 with 5.4 million shares traded as of 2:30 p.m. ET. Average volume has been 2.6 million shares over the past 30 days.
GlaxoSmithKline has a market cap of $132.86 billion and is part of the health care sector and drugs industry. Shares are up 13.6% year to date as of the close of trading on Tuesday.
GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. The company has a P/E ratio of 14.8, below the S&P 500 P/E ratio of 17.7.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full GlaxoSmithKline Ratings Report.
Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.